Received by email:

File: Press Release - 2016-12-09 - Final Close of Private Placement (-Final--).doc



CSE Symbol: IME
OTC PINK Symbol: IMEXF
Frankfurt/Stuttgart Stock Exchanges: DPD2


 
NR-2016-IME-27

 
 IMAGIN MEDICAL CLOSES TRANCHE 2 OF PRIVATE PLACEMENT 

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care
---> for urologists in the early detection of bladder cancer through endoscopes.
    
 Vancouver, B.C. and Boston, MA, December 9 , 2016 - Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart 
--->Stock Exchanges: DPD2) (the "Company") announced today that, further to its press releases of September 13, October 20
--->, and November 1, 2016, it has closed the final tranche of its private placement, through the issuance of an additiona
--->l 3,873,605 units (the "Units") at a price of Cdn $0.08 per Units for gross proceeds of Cdn $309,888.40  (the "Offerin
--->g"). 

Together with the proceeds from Tranche 1 of $385,800, the Company has now closed on a total of $695,688.40. The Compa
--->ny intends to use these proceeds for general working capital purposes, including advancing the development of the i/Bl
--->ue Imaging System for the early detection of cancer through the use of endoscopes.  All shares issued in connection wi
--->th the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale re
--->quirements of applicable securities regulations.
  
Each Unit consists of one common share of the Company and one warrant ("Warrant"), each Warrant entitling the holder t
--->hereof to acquire one additional common share of the Company at a price of $0.12 in the first 12 months and $0.16 in t
--->he 12 months thereafter.
  
Finders' fees in the form of 106,960 warrants and cash payments of $8,556.80 were paid for a portion of the financing 
--->attributable to certain finders' efforts.

 About Imagin Medical  
Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Co
--->mpany believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder c
--->ancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a gr
--->eater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive
---> imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical
--->.com.

ON BEHALF OF THE BOARD:
 
Jim Hutchens,
President & CEO

For further information, contact:
Bill Galine, Investor Relations
Telephone: (775) 737-3292
Email: billgaline@gmail.com

Information set forth in this news release contains forward-looking statements. These statements reflect management's 
--->current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company ca
--->utions that all forward looking statements are inherently uncertain and that actual performance may be affected by a n
--->umber of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, cond
--->itions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied
---> in the forward looking information. Except as required under applicable securities legislation, the Company undertake
--->s no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved
---> the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release
--->. 



File: Press Release - 2016-12-09 - Final Close of Private Placement (-Final--).pdf

890 West Pender Street, Suite 600                                                       133 Hampshire Road
Vancouver, British Columbia                                                             Wellesley, MA, 02481, USA
Canada V6C 1J9                                                                          617-571-6006
778-998-5000                                                                            www.imaginmedical.com




      CSE Symbol: IME                                                                NR-2016-IME-27
      OTC PINK Symbol: IMEXF
      Frankfurt/Stuttgart Stock Exchanges: DPD2


                      IMAGIN MEDICAL CLOSES TRANCHE 2 OF PRIVATE PLACEMENT

      Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish
      a new standard of care for urologists in the early detection of bladder cancer through
      endoscopes.

       Vancouver, B.C. and Boston, MA, December 9 , 2016   Imagin Medical (CSE: IME) (OTC PINK:
      IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the "Company") announced today that,
      further to its press releases of September 13, October 20, and November 1, 2016, it has
      closed the final tranche of its private placement, through the issuance of an additional
      3,873,605 units (the "Units") at a price of Cdn $0.08 per Units for gross proceeds of Cdn
      $309,888.40 (the "Offering").

      Together with the proceeds from Tranche 1 of $385,800, the Company has now closed on a
      total of $695,688.40. The Company intends to use these proceeds for general working capital
      purposes, including advancing the development of the i/Blue Imaging System for the early
      detection of cancer through the use of endoscopes. All shares issued in connection with the
      Offering will be subject to a hold period of four months plus a day from the date of issuance
      and the resale requirements of applicable securities regulations.

      Each Unit consists of one common share of the Company and one warrant ("Warrant"), each
      Warrant entitling the holder thereof to acquire one additional common share of the Company
      at a price of $0.12 in the first 12 months and $0.16 in the 12 months thereafter.

      Finders' fees in the form of 106,960 warrants and cash payments of $8,556.80 were paid for a
      portion of the financing attributable to certain finders' efforts.
 About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer through the
use of endoscopes. The Company believes it will radically improve the way physicians detect
cancer. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth
most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50%
recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced,
ultrasensitive imaging technology is based upon improved optical designs and advanced light
sensors. Learn more at www.imaginmedical.com.


ON BEHALF OF THE BOARD:

Jim Hutchens,
President & CEO

For further information, contact:
Bill Galine, Investor Relations
Telephone: (775) 737-3292
Email: billgaline@gmail.com

Information set forth in this news release contains forward-looking statements. These statements reflect
management's current estimates, beliefs, intentions and expectations; they are not guarantees of future
performance. The Company cautions that all forward looking statements are inherently uncertain and that actual
performance may be affected by a number of material factors, many of which ar e beyond the Company's control.
Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs,
intentions and expectations expressed or implied in the forward looking information. Except as required under
applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-
looking information. The CSE has neither approved nor disapproved the information contained herein and does
not accept responsibility for the adequacy or accuracy of this news release.